ARM’s hybrid 2024 Cell & Gene State of the Industry Briefing will attract over 800+ key stakeholders in the field. This event includes ARM’s annual yearly update on the sector’s progress followed by two noteworthy sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.
Over 800 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
2024 Cell & Gene State of the Industry Briefing Agenda
8:00-8:30am PT | Introduction & Industry Update
Tim Hunt, CEO, Alliance for Regenerative Medicine
8:30-9:00am PT | Featured Speaker – Dr. Peter Marks
Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)
9:00-9:50am PT | A Seminal Moment Arrives for Gene Therapy and Sickle Cell Disease – What’s Next?
Gbola Amusa, M.D., Partner, Chief Scientific Officer, Chardan (Moderator)
Samarth Kulkarni, Ph.D., CEO, CRISPR Therapeutics
Registering for Biotech Showcase?
ARM members will receive a $200 discount off their Biotech Showcase registration fees when they use the VIP code: supARM2024. Remember that a Biotech Showcase registration is not required to attend the Cell & Gene State of the Industry Briefing.